Circulating microRNAs as novel biomarkers of Alzheimer's disease

Zendjabil, Mustapha

doi:10.1016/j.cca.2018.05.039

Cited by 31 publications

(21 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The panel also had the ability to discriminate AD patients from patients with MCI, multiple sclerosis, parkinsonism, major depression, schizophrenia, and bipolar disorder with accuracies of 74-78% [73]. Other studies identifying panels of miRNAs have been reported to discriminate between AD patients and controls with accuracies between 75 and 95% [74][75][76]. A recent review of miRNAs as biomarkers for AD is provided by Nagaraj and colleagues [77] where they report 136 individual miRNAs to be significantly altered between AD and control states from the literature.…”

Section: Mirna Biomarker Panelsmentioning

confidence: 92%

Blood-based molecular biomarkers for Alzheimer’s disease

2019

View full text Add to dashboard Cite

A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need of further studies to achieve the goal of a primary care-based screening algorithm for AD.

show abstract

Section: Mirna Biomarker Panelsmentioning

confidence: 92%

Blood-based molecular biomarkers for Alzheimer’s disease

2019

View full text Add to dashboard Cite

show abstract

“…A brief summary of miRNAs implicated in neurologic disorders is provided in Table 4. In Alzheimer's disease, miRNA alterations can be detected both in the brain and cerebrospinal fluid (CSF) of the patients, and also in the biological fluids, such as plasma and serum, making them potential candidates as biomarkers [275]. The biomarkers currently in use are represented by tau (tubulin-associated unit) proteins and Aβ peptides [276].…”

Section: Mirnas In Nervous System Disordersmentioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

858

583

View full text Add to dashboard Cite

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of regulating mRNA through its degradation and adjusting protein levels. In recent years, extraordinary progress has been made in terms of identifying the origin and exact functions of miRNA, focusing on their potential use in both the research and the clinical field. This review aims at improving the current understanding of these molecules and their applicability in the medical field. A thorough analysis of the literature consulting resources available in online databases such as NCBI, PubMed, Medline, ScienceDirect, and UpToDate was performed. There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Despite present limitations, miRNAs as biomarkers for various conditions remain an impressive research field. As current techniques evolve, we anticipate that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.Biogenesis of miRNA begins in the nucleus, where the transcription of its precursor, primary miRNA or pri-miRNA takes place under the influence of RNA polymerases II and III [11,12]. The resulting molecule is a hairpin-like structure, which contains a loop at one end [11]. This primordial mi-RNA precursor that is usually made up of hundreds of nucleotides is then processed consecutively by two RNase III enzymes [13][14][15]. The first enzyme to act upon the pri-miRNA, which still resides in the nucleus, is called Drosha or DCGR8, and turns it into a new hairpin-like structure of approximately 70 nucleotides, the Precursor-miRNA or pre-miRNA. The latter is then transported to the cytoplasm, with the help of Exportin-5, where it is cleaved again by the Ago2/Dicer complex leading to the short, mature miRNA double strands [16].Further on, one of the strands, usually known as the guide strand, will be integrated into the RNA-induced silencing complex (RISC), while the other one, known as the passenger strand, is going to be degraded, even though in some occasions it has been found to be also functional [17]. In most cases, the strand that contains the less stable 5 end or a uracil at the beginning is more likely to be selected as the guide strand [18][19][20]. In those situations, where the passenger strand is not degraded and both get incorporated into the miRISC complex, the mature miRNA in the guide strand will be the dominant one [21,22].The main role of miRNA in the human body is gene regulation [23] by mediating the degradation of mRNA and also by regulating transcription and translation through canonical and non-canonical mechanisms [4]. The canonical mechanism means that the miRISC complex containing the miRNA guide strand is exerting its action by binding to the targ...

show abstract

“…MicroRNAs (miRNAs), a class of small non-coding RNAs, are involved in post-transcriptional gene repression. Alterations in miRNA abundance occurs in lung tissue, inflammatory cells, and freely circulating cells in blood, and are thought to function both as drivers and modifiers of disease [ 61 , 62 ]. In COPD patients, -miR-124-3p, miR-34a, miR-124, miR-29c and miR-126 are upregulated; -miR-181c, miR-21, miR-146a, miR-98-5bp are downregulated [ 61 ].…”

Section: Mild Cognitive Impairmentmentioning

confidence: 99%

“…In COPD patients, -miR-124-3p, miR-34a, miR-124, miR-29c and miR-126 are upregulated; -miR-181c, miR-21, miR-146a, miR-98-5bp are downregulated [ 61 ]. In MCI/AD, miRNAs (miR-124-3p, miR-34a, miR-124, miR-181c, miR-21, miR-146a, miR-98-5bp) contribute to the development, differentiation, and synaptic plasticity of neuronal cells, and are involved in many neurodegenerative diseases, including AD [ 62 ]. ii.…”

Section: Mild Cognitive Impairmentmentioning

confidence: 99%

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

et al. 2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is characterized by long-term airflow limitation. Early-onset COPD in non-smoker subjects is ≥60 years and in the elderly is often associated with different comorbidities. Cognitive impairment is one of the most common feature in patients with COPD, and is associated with COPD severity and comorbidities. Cognitive impairment in COPD enhances the assistance requirement in different aspects of daily living, treatment adherence, and effectual self-management.This review describes various bioactive compounds of natural marine sources that modulate different targets shared by both COPD and cognitive impairment and hypothesizes a possible link between these two syndromes.

show abstract

Circulating microRNAs as novel biomarkers of Alzheimer's disease

Cited by 31 publications

References 66 publications

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based molecular biomarkers for Alzheimer’s disease

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

Contact Info

Product

Resources

About